The Silver Jubilee (2025) of Insulin Glargine: Introducing the Era of Long‐Acting Insulin Analogues for Diabetes Mellitus
Open Access
- 27 April 2026
- journal article
- review article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (7) , 5527-5541
Abstract
In the year 2000 the first once daily long‐acting bioengineered insulin analogue (LAIA), insulin glargine (‘glargine’), a true basal insulin (BI), became available for clinical use. This led to the decline in the 50‐year‐old era and prominence of the intermediate‐acting insulins, neutral protamine Hagedorn (NPH) and lente, requiring twice daily administration to control the basal metabolism of people with type 1 diabetes (T1DM) and type 2 diabetes (T2DM). This milestone bridged the gap between regimens involving unmodified human insulins of the previous century to those referred to as using ‘designer insulins’, with the introduction 4 years previously of the meal‐time analogue, insulin lispro. The rapid gain in popularity of glargine is explained by its clinical benefits (once‐daily dosing, titration to achieve improved pre‐breakfast plasma glucose, with a lower risk of nocturnal hypoglycaemia compared to NPH, and less frequent blood glucose monitoring). These benefits correlate with the pharmacokinetic/pharmacodynamic characteristics of insulin glargine being closer to physiological BI supply. In T2DM glargine changed the paradigm of insulin substitution by embedding the concept of ‘treating‐to‐target’, by starting BI ‘early’, with focus on near‐normal fasting plasma glucose prior to the introduction of prandial insulin, and more recently in combination with GLP‐1 receptor agonists. These practices/principles have continued with the introduction of additional innovative LAIAs for once‐daily or indeed weekly use. Today glargine remains in widespread worldwide use in people with T1DM and T2DM, is often the initial BI used, while it serves as a reference against which other LAIAs are tested in clinical trials.Keywords
Funding Information
- Università degli Studi di Perugia
This publication has 157 references indexed in Scilit:
- Standards of care for type 2 diabetes in ChinaDiabetes/Metabolism Research and Reviews, 2016
- A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetesDiabetologia, 2008
- Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET studyDiabetologia, 2006
- A randomized multicentre trial of insulin glargine compared with NPH insulin in people with type 1 diabetesDiabetes/Metabolism Research and Reviews, 2005
- Pharmacokinetic and glucodynamic variability: assessment of insulin glargine, NPH insulin and insulin ultralente in healthy volunteers using a euglycaemic clamp techniqueDiabetologia, 2005
- Binding of phenol to R6 insulin hexamers*Biopolymers, 1999
- Use of the short-acting insulin analogue lispro in intensive treatment of Type 1 diabetes mellitus: importance of appropriate replacement of basal insulin and time-interval injection-mealDiabetic Medicine, 1998
- Basal and 24-h C-peptide and insulin secretion rate in normal manDiabetologia, 1987
- Absorption kinetics and action profiles of mixtures of short-and intermediate-acting insulinsDiabetologia, 1984
- PROTAMINE INSULINATEJAMA, 1936